Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics

Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. HCV infection is currently treated with IFNα plus ribavirin for 24 to 48 weeks. This demanding therapy fails in up to 50% of patients, so the use of pharmacogenetic biomarkers to predict the outcome of treatment w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tavis, John E, Donlin, Maureen J, Aurora, Rajeev, Fan, Xiaofeng, Di Bisceglie, Adrian M
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2011
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3092093/
https://ncbi.nlm.nih.gov/pubmed/21345258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/gm222
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky